Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles

Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles

Background Trans-acting programmed death-ligand 1 (PD-L1) derives from malignant cells in three known forms. High levels of secreted splice variant PD-L1 (sPD-L1), ADAM10/ADAM17-shed sPD-L1, and PD-L1-positive extracellular vesicles (evPD-L1) each predict poor prognosis and limited response to PD-(L...

Full description

Saved in:

Bibliographic Details
Main Authors:	Haidong Dong, Svetomir N Markovic, Aaron S Mansfield, Jacob J Orme, Elizabeth Ann L Enninga, Fabrice Lucien-Matteoni, Heather Dale, Edwin Burgstaler, Susan M Harrington, Matthew K Ball, Sean S Park, Mathew S Block, Yiyi Yan, Roxana S Dronca, Jeffrey L Winters
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2020-10-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/8/2/e001113.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Infiltration of CD8+ cytotoxic T-cells and expression of PD-1 and PD-L1 in ovarian clear cell carcinoma
by: Mengdi Fu, et al.
Published: (2025-02-01)

Ocular adverse events in PD-1 and PD-L1 inhibitors
by: James Murray, et al.
Published: (2021-07-01)

PD-L1-expressing natural killer cells predict favorable prognosis and response to PD-1/PD-L1 blockade in neuroblastoma
by: Mengjia Song, et al.
Published: (2024-12-01)

Association of PD-1 and PD-L1 Genetic Polymorphyisms with Type 1 Diabetes Susceptibility
by: Chenyue Qian, et al.
Published: (2018-01-01)

Depth-dependent PD-L1 sampling of head and neck squamous cell carcinoma (HNSCC) – implications for PD-1/PD-L1 checkpoint inhibitor immunotherapy
by: Madhusudan Roy, et al.
Published: (2024-03-01)

PD-L1 antibodies-armed exosomal vaccine for enhanced cancer immunotherapy by simultaneously in situ activating T cells and blocking PD-1/PD-L1 axis
by: Xinyue Dai, et al.
Published: (2022-12-01)

A bispecific anti-PD-1 and PD-L1 antibody induces PD-1 cleavage and provides enhanced anti-tumor activity
by: Diana I. Albu, et al.
Published: (2024-12-01)

A computational chemistry-based approach to optimizing PD-1/PD-L1 inhibitors
by: Meijuan Zhai, et al.
Published: (2025-01-01)

Optimizing PD-L1/PD-1 therapies: Immune checkpoint inhibitors in nasopharyngeal carcinoma
by: Madhan Krishnan, et al.
Published: (2024-12-01)

Periodontitis promotes tumor growth and immune evasion via PD-1/PD-L1
by: Suli Wang, et al.
Published: (2024-11-01)

Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies
by: Alberto Puccini, et al.
Published: (2020-05-01)

PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer
by: Thomas J Ettrich, et al.
Published: (2021-07-01)

Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse models
by: Taiki Kurino, et al.
Published: (2020-05-01)

Notch Signaling and PD-1/PD-L1 Interaction in Hepatocellular Carcinoma: Potentialities of Combined Therapies
by: Annapaola Montagner, et al.
Published: (2024-12-01)

Bibliometric analysis of the research landscape of PD-1/PD-L1 inhibitors in the treatment of bowel cancer
by: Qingwei Luo, et al.
Published: (2025-02-01)

Letter to the editor, “Depth-dependent PD-L1 sampling of head and neck squamous cell carcinoma (HNSCC) – Implications for PD-1/PD-L1 checkpoint inhibitor immunotherapy.”
by: Geetha Shanmugam
Published: (2024-09-01)

Oxymatrine Inhibits PD-L1 by Downregulating IFN-γ to Promote Ferroptosis and Enhance Anti-PD-L1 Efficacy in Liver Cancer
by: Nong Y, et al.
Published: (2024-12-01)

CD8+PD-1+ to CD4+PD-1+ ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers
by: Francois-Xavier Danlos, et al.
Published: (2022-02-01)

PD-L2 act as an independent immune checkpoint in colorectal cancer beyond PD-L1
by: Lvyun Zhu, et al.
Published: (2024-12-01)

The Potential of PD-1 and PD-L1 as Prognostic and Predictive Biomarkers in Colorectal Adenocarcinoma Based on TILs Grading
by: Nur Rahmah Rasyid, et al.
Published: (2024-11-01)

Comparison of the Efficacy and Safety of PD‐1/PD‐L1 Inhibitors in the Treatment of Small Cell Lung Cancer
by: Qichen Zhang, et al.
Published: (2025-01-01)

The Increase of Circulating PD-1- and PD-L1-Expressing Lymphocytes in Endometriosis: Correlation with Clinical and Laboratory Parameters
by: Monika Walankiewicz, et al.
Published: (2018-01-01)

PD-1/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies
by: Menglei Jin, et al.
Published: (2024-11-01)

Enhancing immunotherapy through PD‐L1 upregulation: the promising combination of anti‐PD‐L1 plus mTOR inhibitors
by: Anna Hernández‐Prat, et al.
Published: (2025-01-01)

PD-1/PD-L1 inhibitors related adverse events: A bibliometric analysis from 2014 to 2024
by: Qingya Song, et al.
Published: (2025-12-01)

Current perspectives on tertiary lymphoid structures and PD-1/PD-L1 signaling pathway in the immunotherapy of hepatocellular carcinoma
by: Hao-Dong QIAO, et al.
Published: (2023-10-01)

Identification of novel PD-1/PD-L1 small molecule inhibitors: virtual screening, synthesis and in vitro characterisation
by: Tingting Wu, et al.
Published: (2024-12-01)

From PD-1/PD-L1 to tertiary lymphoid structures: Paving the way for precision immunotherapy in cholangiocarcinoma treatment
by: Fang-Ju Huang, et al.
Published: (2025-12-01)

The MHC-I-dependent neoantigen presentation pathway predicts response rate to PD-1/PD-L1 blockade
by: Yuchen Zhang, et al.
Published: (2024-11-01)

Risk of immune‐related pneumonitis for PD1/PD‐L1 inhibitors: Systematic review and network meta‐analysis
by: Yafang Huang, et al.
Published: (2019-05-01)

Cellular mechanisms of combining innate immunity activation with PD-1/PD-L1 blockade in treatment of colorectal cancer
by: Qi Xie, et al.
Published: (2024-11-01)

HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma
by: Xu Chen, et al.
Published: (2020-05-01)

Role of PD-1/PD-L1 signaling axis in oncogenesis and its targeting by bioactive natural compounds for cancer immunotherapy
by: Yogesh Godiyal, et al.
Published: (2024-12-01)

PD-1/PD-L1在膀胱癌患者外周血T细胞和肿瘤细胞表达
by: 龙兆麟, et al.
Published: (2017-01-01)

Relationship between the ultrasound features of different molecular subtypes of breast cancer and positive PD-1/PD-L1 expression
by: Ruiqian Yan, et al.
Published: (2025-02-01)

Follicular helper-T cells restore CD8+-dependent antitumor immunity and anti-PD-L1/PD-1 efficacy
by: Francois Ghiringhelli, et al.
Published: (2021-06-01)

Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice
by: Alessandro Russo, et al.
Published: (2020-10-01)

Brain metastasis PD-L1 and CD8 expression is dependent on primary tumor type and its PD-L1 and CD8 status
by: Fabien Forest, et al.
Published: (2020-10-01)

EXPRESSION AND CLINICAL CORRELATION OF PD-1/PD-L1 AND VE1(BRAFP.V600E) IN PEDIATRIC LANGERHANS CELL HISTIOCYTOSIS
by: sneha tandon, et al.
Published: (2023-04-01)

Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances
by: Jeffrey Schlom, et al.
Published: (2020-05-01)